Education
About Us
Working with TipRanks
Follow Us
Amphastar Pharmaceuticals (AMPH)
NASDAQ:AMPH
Earnings Data
Report Date
Mar 04, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
0.92Last Year’s EPS
0.92Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
Amphastar Pharmaceuticals showed resilience with strong sales growth in key products and strategic pipeline expansions, despite facing declines in specific product sales and increased competition. The litigation provision and reduced net income were notable challenges.Company Guidance
Strong Quarterly Performance
Amphastar Pharmaceuticals achieved net revenues of $191.8 million and a GAAP net income of $17.4 million or $0.37 per diluted share for Q3 2025. On a non-GAAP basis, adjusted net income was $44.7 million or $0.93 per diluted share.
BAQSIMI and Primatene MIST Growth
BAQSIMI delivered $53.6 million in total sales, up 14% year-over-year, while Primatene MIST sales increased by 11% year-over-year, indicating strong consumer engagement in the OTC respiratory space.
Pipeline Expansion
Amphastar expanded its pipeline with an exclusive in-licensing agreement, securing U.S. and Canadian rights to three novel peptide candidates targeting oncology and ophthalmology markets.
Regulatory Progress
FDA approval of iron sucrose injection, AMP-002, was achieved, generating $2.4 million in sales this quarter.
Manufacturing Expansion
Amphastar is set to quadruple production capacity at its Rancho Cucamonga headquarters, strengthening operational agility.
AMPH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AMPH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 06, 2025 | $24.23 | $24.03 | -0.83% |
Aug 07, 2025 | $21.62 | $23.81 | +10.13% |
May 07, 2025 | $24.43 | $24.65 | +0.90% |
Feb 27, 2025 | $31.49 | $28.43 | -9.72% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Amphastar Pharmaceuticals (AMPH) report earnings?
Amphastar Pharmaceuticals (AMPH) is schdueled to report earning on Mar 04, 2026, After Close (Confirmed).
What is Amphastar Pharmaceuticals (AMPH) earnings time?
Amphastar Pharmaceuticals (AMPH) earnings time is at Mar 04, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AMPH EPS forecast?
AMPH EPS forecast for the fiscal quarter 2025 (Q4) is 0.92.